Table 1 The clinical characteristics of patients
Characteristics | RP patients with airway involvement |
|---|---|
Number of patients | 52 |
 Treated | 13 (25.0%) |
 Untreated | 39 (75.0%) |
Age (year)a | 48 [37.75-54.25] |
Course of disease (month)a,b | 8.5 [3.75-12] |
Sex | |
 Male | 33 (63.5%) |
 Female | 19 (36.5%) |
Main symptoms | |
 Cough | 47 (90.4%) |
 Excessive sputum | 31 (59.6%) |
 Shortness of breath | 40 (76.9%) |
 Sore throat | 5 (9.6%) |
 Hoarseness | 11 (21.2%) |
 Chest pain | 7 (13.5%) |
 Fever | 13 (25.0%) |
Commorbidities | 9 (17.3%) |
 Malignancy | 2 (22.2%) |
  Prostate cancer | 1 (11.1%) |
  Non-Hodgkin lymphoma | 1 (11.1%) |
 Other autoimmune diseases | 3 (33.3%) |
  EGPA | 2 (22.2%) |
  Hashimoto’s throiditis | 1 (11.1%) |
 Nodular goiter | 2 (22.2%) |
 Metabolic disease | 2 (22.2%) |
Serological index | |
 Inflammatory markersa | |
  ESR (mm/h) | 39.5 [20-59] (n = 44) |
  CRP (mg/L) | 1.24 [0.29-7.75] (n = 40) |
 Complete blood counta | |
  WBC (10^9/L) | 9.54 [7.69-12.33] (n = 48) |
  Neutrophil (%) | 71.75 [63.3-78.8] (n = 48) |
  Platelet (10^9/L) | 254 [134-342.25] (n = 46) |
  Hemoglobin (g/L) | 113 [105-120.5] (n = 47) |
 Autoimmune markers | |
  RF ( +) (n = 41) | 0 (0.0%) |
  MPO ( +) (n = 37) | 1 (2.7%) |
  PRO-3 ( +) (n = 37) | 1 (2.7%) |
 ANA ( ±) (n = 39) | 5 (12.8%) |
Lung function tests | 36 (69.2%) |
 Five grades to evaluate airway obstruction | 36 (69.2%) |
  Normal | 1 ( 2.8%) |
  Mild | 4 (11.1%) |
  Moderate | 5 (13.9%) |
  Severe | 13 (36.1%) |
  Very severe | 13 (36.1%) |
 GOLD system | 21 (58.3%) |
  Stage I | 0 (0.0%) |
  Stage II | 10 (47.6%) |
  Stage III | 7 (33.3%) |
  Stage IV | 4 (19.0%) |
Bronchoscopy | 43 (82.7%) |
 Positive | 43 (100%) |
Methods of diagnosis | |
 Auricular biopsy (n = 37) | 28 (75.7%) |
 Bronchoscopic biopsy (n = 36) | 4 (11.1%) |
 Biopsy of nasal septum (n = 2) | 1 (50.0%) |
 Clinically | 19 (36.5%) |